rss
J Neurol Neurosurg Psychiatry 2007;78:699-701 doi:10.1136/jnnp.2006.103465
  • Paper

Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study

  1. Jean-Marc Bugnicourt1,
  2. Bertrand Roussel2,
  3. Blaise Tramier3,
  4. Chantal Lamy1,
  5. Olivier Godefroy1
  1. 1Department of Neurology and Laboratoire de Neurosciences Fonctionnelles et Pathologies (UMR CNRS 8160), University Hospital of Amiens, France
  2. 2Department of Haematology and Thrombosis, University Hospital of Amiens, France
  3. 3Medical Information Department, University Hospital of Amiens, France
  1. Correspondence to:
 Dr J M Bugnicourt
 Service de Neurologie, CHU Amiens 80054, Amiens Cedex, France; bugnicourt.jean-marc{at}chu-amiens.fr
  • Received 1 August 2006
  • Accepted 17 December 2006
  • Revised 14 December 2006
  • Published Online First 22 December 2006

Abstract

Background: High plasma concentrations of factor VIII (FVIII) and von Willebrand factor (VWF) have been recently associated with a moderately increased risk of venous thrombosis, but their roles in cerebral sinus and venous thrombosis (CSVT) have not been addressed. To determine whether elevation of FVIII and VWF is more frequent in CSVT, we analysed plasma levels of FVIII and VWF in a case control study.

Methods: The study population consisted of 25 consecutive patients (of whom nine were excluded) admitted for CSVT to the Department of Neurology, Amiens University Hospital, France, from January 1997 to December 2002, for a general screening for thrombophilia. Sixty-four healthy subjects matched for age and sex formed the group control.

Results: Mean FVIII (CSVT: 167.3 (SD 48.8) IU/dl; control group: 117.9 (39.8) IU/dl; p = 0.001) and VWF levels (CSVT: 165.4 (76.5)%; control group: 108.5 (27.8)%; p = 0.01) were significantly higher in the CSVT group. Using the 95th percentile of the control group as the cut off value, elevated FVIII (>190 IU/dl) occurred in 25% (4/16) (p = 0.005) and elevated VWF (>168%) in 37.5% (6/16) of patients with CSVT (p<0.001). Using previously reported cut off values (>150 IU/dl or >150%) showed the same results (FVIII: p = 0.005; VWF: p = 0.009).

Conclusion: Our study suggests that elevation of plasma factor VIII levels is the most common prothrombotic risk factor for CSVT. Elevation of VWF is also associated with an increased risk of CSVT but its effect seems to be partly mediated through FVIII.

Footnotes

  • Published Online First 22 December 2006

  • Competing interests: None.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs